{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:32:24Z","timestamp":1787931144756,"version":"build-2784847793"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.drudis.2023.103818","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T20:04:55Z","timestamp":1698955495000},"page":"103818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders"],"prefix":"10.1016","volume":"28","author":[{"given":"Taeho Greg","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasha A.","family":"Davoudian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Sanacora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2023.103818_b0005","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2023.103818_b0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4088\/JCP.14m09298","article-title":"The economic burden of adults with major depressive disorder in the United States (2005 and 2010)","volume":"76","author":"Greenberg","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.drudis.2023.103818_b0015","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1017\/S2045796021000275","article-title":"Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019","volume":"30","author":"Yang","year":"2021","journal-title":"Epidemiol Psych Sci"},{"key":"10.1016\/j.drudis.2023.103818_b0020","series-title":"Trauma and Posttraumatic Stress Disorder: Global Perspectives from the WHO World Mental Health Surveys","author":"Bromet","year":"2018"},{"key":"10.1016\/j.drudis.2023.103818_b0025","unstructured":"Gordon JA. One Year. In: COVID-19 and Mental Health. Published April 9, 2021. www.nimh.nih.gov\/about\/director\/messages\/2021\/one-year-in-covid-19-and-mental-health [Accessed 29 October, 2023]."},{"key":"10.1016\/j.drudis.2023.103818_b0030","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD Report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4088\/JCP.v63n0810","article-title":"Identification of a claims data \u201csignature\u201d and economic consequences for treatment-resistant depression","volume":"63","author":"Corey-Lisle","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.drudis.2023.103818_b0040","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0045","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.drudis.2023.103818_b0050","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.drudis.2023.103818_b0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2023.103818_b0060","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.drudis.2023.103818_b0065","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.neuron.2014.10.027","article-title":"Medicines for the mind: policy-based \u201cpull\u201d incentives for creating breakthrough CNS drugs","volume":"84","author":"Choi","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2023.103818_b0070","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Curr Biol"},{"key":"10.1016\/j.drudis.2023.103818_b0075","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","article-title":"The neural basis of psychedelic action","volume":"25","author":"Kwan","year":"2022","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.drudis.2023.103818_b0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.drudis.2023.103818_b0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0095","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2023.103818_b0100","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"Eclinicalmedicine"},{"key":"10.1016\/j.drudis.2023.103818_b0105","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2023.103818_b0275","doi-asserted-by":"crossref","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial, JAMA, 330(9), 2023, 843-853.","DOI":"10.1001\/jama.2023.14530"},{"key":"10.1016\/j.drudis.2023.103818_b0110","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder","volume":"330","author":"Raison","year":"2023","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.drudis.2023.103818_b0115","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.drudis.2023.103818_b0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/appi.ajp.162.2.214","article-title":"A multidimensional meta-analysis of psychotherapy for PTSD","volume":"162","author":"Bradley","year":"2005","journal-title":"Am J Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0125","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1037\/ser0000143","article-title":"Psychotherapy practices for veterans with PTSD among community-based providers in Texas","volume":"15","author":"Finley","year":"2018","journal-title":"Psychol Serv"},{"key":"10.1016\/j.drudis.2023.103818_b0130","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2023.103818_b0135","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2023.103818_b0140","unstructured":"MAPS. Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 Trial; 2023. https:\/\/maps.org\/2023\/01\/05\/prior-positive-results-confirmed\/ [Accessed 29 October 2023]."},{"key":"10.1016\/j.drudis.2023.103818_b0145","doi-asserted-by":"crossref","first-page":"20442","DOI":"10.1038\/s41598-020-75706-1","article-title":"MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study","volume":"10","author":"Wolfson","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2023.103818_b0150","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","article-title":"Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study","volume":"235","author":"Danforth","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2023.103818_b0155","unstructured":"Small Pharma. Small Pharma reports positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder. https:\/\/smallpharma.com\/press-releases\/positive-topline-results-from-phase-iia-trial-of-spl026-in-major-depressive-disorder\/ [Accessed 29 October 2023]."},{"key":"10.1016\/j.drudis.2023.103818_b0160","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"key":"10.1016\/j.drudis.2023.103818_b0165","unstructured":"GH Research. GH Research Announces Successful Outcome of the Phase 2 Part of Its Phase 1\/2 Clinical Trial of GH001 in Treatment-Resistant Depression. https:\/\/investor.ghres.com\/news-releases\/news-release-details\/gh-research-announces-successful-outcome-phase-2-part-its-phase [Accessed 29 October 2023]."},{"key":"10.1016\/j.drudis.2023.103818_b0170","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","article-title":"Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder","volume":"47","author":"D\u2019Souza","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2023.103818_b0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled Phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0180","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.drudis.2023.103818_b0185","unstructured":"MindMed. MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD). https:\/\/mindmed.co\/news\/press-release\/mindmed-collaborators-announce-positive-topline-data-from-phase-2-trial-of-lysergide-lsd-in-major-depressive-disorder-mdd\/ [Accessed 29 October 2023]."},{"key":"10.1016\/j.drudis.2023.103818_b0190","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1177\/02698811221116926","article-title":"Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review","volume":"36","author":"Breeksema","year":"2022","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.drudis.2023.103818_b0195","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamapsychiatry.2023.0099","article-title":"Studying harms is key to improving psychedelic-assisted therapy\u2014participants call for changes to research landscape","volume":"80","author":"McNamee","year":"2023","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0200","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2023.103818_b0205","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","author":"Droogmans","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.drudis.2023.103818_b0210","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.drudis.2023.103818_b0215","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/a-1524-2794","article-title":"Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports","volume":"54","author":"Nayak","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.drudis.2023.103818_b0220","article-title":"Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002\u20132019","volume":"16","author":"Walsh","year":"2022","journal-title":"Addict Behav Rep"},{"key":"10.1016\/j.drudis.2023.103818_b0225","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamapsychiatry.2022.2546","article-title":"Preparing for the bursting of the psychedelic hype bubble","volume":"79","author":"Yaden","year":"2022","journal-title":"JAMA Psychiat"},{"key":"10.1016\/j.drudis.2023.103818_b0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","article-title":"Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans","volume":"142","author":"Heal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2023.103818_b0235","article-title":"Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of \u2018magic mushroom\u2019 consumption","author":"Morton","year":"2022","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.drudis.2023.103818_b0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti","year":"2018","journal-title":"Brain Sci"},{"key":"10.1016\/j.drudis.2023.103818_b0245","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00213-022-06066-z","article-title":"Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants","volume":"239","author":"M\u00fcller","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drudis.2023.103818_b0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2023.103818_b0255","first-page":"91","article-title":"Pharmacologic use of niacin","volume":"16","author":"Prousky","year":"2011","journal-title":"Complementary Heal Pract Rev"},{"key":"10.1016\/j.drudis.2023.103818_b0260","unstructured":"AMA. CPT\u00ae Editorial Summary of Panel Actions. www.ama-assn.org\/system\/files\/cpt-summary-panel-actions-feb-2023.pdf [Accessed 29 October 2023]."},{"key":"10.1016\/j.drudis.2023.103818_b0265","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2023.103818_b0270","doi-asserted-by":"crossref","DOI":"10.1177\/24705470211020446","article-title":"Emerging therapeutics based on the amino acid neurotransmitter system: an update on the pharmaceutical pipeline for mood disorders","volume":"5","author":"Hecking","year":"2021","journal-title":"Chronic Stress"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644623003343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:10:37Z","timestamp":1761225037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644623003343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1359644623003343"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103818","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2023.103818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103818"}}